Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Jun 02, 2023 8:35pm
187 Views
Post# 35477984

RE:Regardless ,the die is set..

RE:Regardless ,the die is set..Mayl 2017:  ONC announced results from IND.213 and were granted FDA Fast Track designation.  At that time they also annoucned they were ready to enter a phase three trial. 

SIX YEARS LATER we will have results from their second (PHASE 2) randomized trial in mBC.

That's a long wait for phase 3!

Clearly, if the results tomorrow are anyting less than astounding, ONC will remain unpartnered for Pela/Pax Phase 3 and the SP will be treading water for another half decade. 

This does seem like ONC's best shot on net and it better be good. I, for one, cannot bear to see ONC tap the ATM for a couple more years and raise the float well above 100 million shares outstanding. 

Times up, let's go.


<< Previous
Bullboard Posts
Next >>